CervoMed (CRVO) Other Non-Current Liabilities (2011 - 2022)

CervoMed (CRVO) posted Other Non-Current Liabilities of $12.4 million for Q4 2022, up 895571.0% sequentially from $1386.0 in Q4 2017.

CervoMed (CRVO) Other Non-Current Liabilities (2011 - 2022) Analysis & Trends

CervoMed has reported Other Non-Current Liabilities for 6 years, with the latest figure at $12.4 million in Q4 2022.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $12.4 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $12.4 million (changed N/A YoY) and the FY2022 annual result came in at $12.4 million, changed N/A from the prior year.
Other Non-Current Liabilities climbed to $12.4 million in Q4 2022 per CRVO's latest filing, from $1386.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $12.4 million in Q4 2022 and troughed at $12.4 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	CervoMed	26.64 Mn	26.64 Mn	-

Download Data